Intralesional lipid-complexed cytokine/superantigen immunogene therapy for spontaneous canine tumors

Cancer Immunology, Immunotherapy

Volumn 52, Issue 8, 2003, Pages 473-480

  Thamm, Douglas H ^a   Kurzman, Ilene D ^a   Macewen, E Gregory ^a,b   Feinmehl, Rhonda ^c   Towell, Todd L ^d   Longhofer, Susan L ^d   Johnson, Christine M ^d   Geoly, Frank J ^d   Stinchcomb, Dan T ^d  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c Veterinary Medical Referral Service   (United States)

^d HESKA CORPORATION   (United States)

Author keywords

Canine; Cytokine; Gene therapy; Immunotherapy; Superantigen

Indexed keywords

CD3 ANTIGEN; CD79A ANTIGEN; CYTOKINE; INTERLEUKIN 2; LIPID; MESSENGER RNA; PLASMID DNA; STAPHYLOCOCCUS ENTEROTOXIN A; SUPERANTIGEN;

ANIMAL EXPERIMENT; ANIMAL LAMENESS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; DIARRHEA; DNA DETERMINATION; DOG; DOG DISEASE; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; GENE CONSTRUCT; GENE EXPRESSION; GENE THERAPY; GENETIC ANALYSIS; GENETIC CODE; HISTOPATHOLOGY; IMMUNOGENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INJECTION; LETHARGY; LYMPHOCYTIC INFILTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; SAMPLE; SOFT TISSUE SARCOMA; STAPHYLOCOCCUS AUREUS; TIME; TUMOR; VOMITING;

ANIMALS; DOG DISEASES; DOGS; ENTEROTOXINS; FEMALE; GENE THERAPY; IMMUNOTHERAPY; INJECTIONS, INTRALESIONAL; INTERLEUKIN-2; LIPID METABOLISM; MALE; NEOPLASMS; PLASMIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STAPHYLOCOCCUS AUREUS; SUPERANTIGENS; TRANSFECTION;

EID: 0042594504     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-003-0387-6     Document Type: Article

References (30)

1. Silagi S, Dutkowski R, Schaefer A (1988) Eradication of mouse melanoma by combined treatment with recombinant human interleukin-2 and recombinant murine interferon-gamma. Int J Cancer 41:315
2. Yeung RS, Vollmer C, Taylor DD, Palazzo J, Weese JL (1992) Intratumoral rIL-2 based immunotherapy in B16 melanoma. J Surg Res 53:203
3. Den Otter W, Hill FWG, Klein WR, Koten JW, Sterenberg PA, De Mulder PHM, Rhode C, Stewart R, Faber JAJ, Ruitenberg EJ, Rutten VPMG (1995) Therapy of bovine ocular squamous-cell carcinoma with local doses ofinterleukin-2: 67% complete regressions after 20 months of follow-up. Cancer Immunol Immunother 41:10
4. DeStefani A, Valente G, Forni G, Lerda W, Ragona R, Cortesina G (1996) Treatment of oral cavity and oropharynx squamous cell carcinoma with perilymphatic interleukin-2: clinical and pathologic correlations. J Immunother 19:125
5. Farkkila M, Jaaskelainen J, Kallio M, Blomstedt G, Raininko R, Virkkunen P, Pateau A, Sarelin H, Mantyla M (1994) Randomised, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastoma. Br J Cancer 70:138
6. Mattijssen V, De Mulder PH, De Graeff A, Hupperets PS, Joosten F, Ruiter DJ, Bier H, Palmer PA, Van den Broek P (1994) Intratumoral PEG-interleukin-2 therapy in patients with locoregionally recurrent head and neck squamous-cell carcinoma. Ann Oncol 5:957
7. Forni G, Giovarelli M, Cavallo E, Consalvo M, Allione A, Modesti A, Muisani P, Colombo MP (1993) Cytokine-induced tumor immunogenicity: from exogenous cytokines to gene therapy. J Immunother 14:253
8. Dow SW, Fradkin LG, Liggitt DH, Willson AP, Heath TD, Potter TA (1999) Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol 163:1552
9. Fox BA, Drury M, Hu HM, Cao Z, Huntzicker EG, Qie W, Urba WJ (1998) Lipofection indirectly increases expression of endogenous major histocompatibility complex class I molecules on tumor cells. Cancer Gene Ther 5:307
10. Hofland H, Huang L (1995) Inhibition of human ovarian carcinoma cell proliferation by liposome-plasmid DNA complex. Biochem Biophys Res Commun 207:492
11. Galanis E, Hersh EM, Stopeck AT, Gonzalez R, Burch P, Spier C, Akporiaye ET, Rinehart JJ, Edmonson J, Sobol RE, Forscher C, Sondak VK, Lewis BD, Unger EC, O'Driscoll M, Selk L, Rubin J (1999) Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience. J Clin Oncol 17:3313
12. Stopeck AT, Hersh EM, Akporiaye ET, Harris DT, Grogan T, Unger E, Warneke J, Schluter SF, Stahl S (1997) Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 15:341
13. Stopeck, A.T, Jones A, Hersh EM, Thompson JA, Finucane DM, Gutheil JC, Gonzalez R (2001) Phase II study of direct intralesional gene transfer of Allovectin-7, an HLA-B7/Beta-2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res 7:2285
14. Daniels GA, Galanis E (2001) Immunotherapy of renal cell carcinoma by intratumoral administration of an IL-2 cDNA/DMRIE/DOPE lipid complex. Curr Opin Mol Ther 3:70
15. Gleich LL, Gluckman JL, Nemunaitis J, Suen JY, Hanna E, Wolf GT, Coltrera MD, Villaret DB, Wagman L, Castro D, Gapany M, Carroll W, Gillespie D, Selk LM (2001) Clinical experience with HLA-B7 plasmid DNA/lipid complex in advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 127:775
16. Belldegrun A, Tso CL, Zisman A, Naitoh J, Said J, Pantuck AJ, Hinkel A, deKernion J, Figlin R (2001) Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther 12:883
17. Lando PA, Hedlund G, Dohlsten M, Kalland T (1991) Bacterial superantigens as anti-tumour agents: induction of tumour cytotoxicity in human lymphocytes by Staphylococcal enterotoxin A. Cancer Immunol Immunother 33:231
18. Micusan VV, Thibodeau J (1993) Superantigens of microbial origin. Sem Immunol 5:3
19. Sriskandan S, Evans TJ, Cohen J (1996) Bacterial superantigen-induced human lymphocyte responses are nitric oxide dependent and mediated by IL-12 and IFN-gamma. J Immunol 156:2430
20. McCormack JE, Callahan JE, Kappler J, Marrack PC (1993) Profound deletion of mature T cells in vivo by chronic exposure to exogenous superantigen. J Immunol 150:3785
21. Dow SW, Potter TA (1997) Expression of bacterial superantigen genes in mice induces localized mononuclear cell inflammatory responses. J Clin Invest 99:2616
22. Shrayer DP, Kouttab N, Hearing VJ, Wanebo HJ (1998) Immunization of mice with melanoma cells transfected to secrete the superantigen, staphylococcal enterotoxin A. Cancer immunol Immunother 46:7
23. Tordsson JM, Ohlsson LG, Abrahmsen LB, Karlstrom PJ, Lando PA, Brodin TN (2000) Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma. Cancer Immunol Immunother 48:691
24. Dow SW, Elmslie RE, Wilson AP, L R, Gorman C, Potter TA (1998) In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J Clin Invest 101:2406
25. Vail DM, MacEwen EG (2000) Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 18:781
26. Kuntz C, Dernell W, Powers BE, Devitt C, Straw RC, Withrow SJ (1997) Prognostic factors for surgical treatment of soft-tissue sarcomas in dogs: 75 cases (1986-1996). J Am Vet Med Assoc 211:1147
27. Nomura T, Nakajima S, Kawabata K, Yamashita F, Takakura Y, Hashida M (1997) Intratumoral pharmacokinetics and in vivo gene expression of naked plasmid DNA and its cationic liposome complexes after direct gene transfer. Cancer Res 57:2681
28. Brehm D, Steinberg HM, Haviland J, Van Winkle T (1995) A retrospective evaluation of 51 cases of peripheral nerve sheath tumors in the dog. J Am An Hosp Assoc 31:349
29. Graves G, Bjorling D, Mahaffey E (1988) Canine hemangiopericytoma: 23 cases (1967-1984). J Am Vet Med Assoc 192:99
30. Postorino N, Berg R, Powers BE, McChesney A, Taylor R, Withrow SJ (1988) Prognostic factors for canine hemangiopericytoma: 50 cases (1979-1984). J Am An Hosp Assoc 24:501